JPMorgan Chase & Co. Grows Holdings in Syros Pharmaceuticals Inc (NASDAQ:SYRS)

JPMorgan Chase & Co. raised its position in shares of Syros Pharmaceuticals Inc (NASDAQ:SYRS) by 15.9% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 126,530 shares of the company’s stock after purchasing an additional 17,330 shares during the quarter. JPMorgan Chase & Co. owned 0.48% of Syros Pharmaceuticals worth $1,926,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in SYRS. Schwab Charles Investment Management Inc. bought a new stake in shares of Syros Pharmaceuticals during the 2nd quarter valued at about $343,000. Rhumbline Advisers bought a new stake in shares of Syros Pharmaceuticals during the 2nd quarter valued at about $198,000. Bank of New York Mellon Corp grew its stake in shares of Syros Pharmaceuticals by 157.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 30,024 shares of the company’s stock valued at $483,000 after purchasing an additional 18,382 shares during the period. Teachers Advisors LLC grew its stake in shares of Syros Pharmaceuticals by 360.5% during the 2nd quarter. Teachers Advisors LLC now owns 22,718 shares of the company’s stock valued at $366,000 after purchasing an additional 17,785 shares during the period. Finally, TIAA CREF Investment Management LLC grew its stake in shares of Syros Pharmaceuticals by 646.3% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 34,390 shares of the company’s stock valued at $553,000 after purchasing an additional 29,782 shares during the period. Institutional investors and hedge funds own 57.96% of the company’s stock.

Syros Pharmaceuticals Inc (NASDAQ SYRS) opened at $10.51 on Tuesday. Syros Pharmaceuticals Inc has a twelve month low of $6.30 and a twelve month high of $24.38. The company has a market capitalization of $276.38 and a P/E ratio of -6.04.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Wednesday, November 8th. The company reported ($0.53) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.53). analysts anticipate that Syros Pharmaceuticals Inc will post -2.12 EPS for the current year.

In other news, Director Srinivas Akkaraju acquired 109,774 shares of Syros Pharmaceuticals stock in a transaction on Thursday, December 14th. The shares were acquired at an average price of $9.03 per share, with a total value of $991,259.22. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Jeremy P. Springhorn acquired 15,000 shares of Syros Pharmaceuticals stock in a transaction on Friday, December 15th. The stock was purchased at an average cost of $9.08 per share, for a total transaction of $136,200.00. The disclosure for this purchase can be found here. 33.60% of the stock is currently owned by insiders.

A number of equities research analysts have issued reports on the company. Piper Jaffray Companies restated an “overweight” rating and set a $30.00 price target on shares of Syros Pharmaceuticals in a research note on Tuesday, October 31st. HC Wainwright reaffirmed a “hold” rating and set a $10.00 price objective on shares of Syros Pharmaceuticals in a research report on Thursday, December 21st. Oppenheimer reaffirmed a “buy” rating and set a $28.00 price objective on shares of Syros Pharmaceuticals in a research report on Thursday, December 7th. Zacks Investment Research cut Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Finally, Roth Capital initiated coverage on Syros Pharmaceuticals in a research report on Monday, October 23rd. They set a “neutral” rating and a $15.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $22.23.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by BBNS and is owned by of BBNS. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://baseballnewssource.com/markets/syros-pharmaceuticals-inc-syrs-shares-bought-by-jpmorgan-chase-co/1820074.html.

Syros Pharmaceuticals Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Institutional Ownership by Quarter for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.